Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials: An alternative view

Clinical Breast Cancer

Volumn 2, Issue 1, 2001, Pages 41-46

  Costantino, Joseph P ^b   Vogel, Victor G ^c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c NONE

Author keywords

Chemoprevention; Hormone replacement therapy; Risk assessment; Tamoxifen

Indexed keywords

PLACEBO; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CENTER; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CHEMOPROPHYLAXIS; CONTROLLED STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; METHODOLOGY; MORBIDITY; PATIENT SELECTION; PUBLIC HEALTH; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 0035003842     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2001.n.009     Document Type: Review

References (13)

1. B Fisher JP Costantino DL Wickerham Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1998 1371 1388
2. JP Costantino MH Gail D Pee Validation studies for models projecting the risk of invasive and total breast cancer incidence J Natl Cancer Inst 91 1999 1541 1548
3. T Powles R Eeles S Ashley Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial Lancet 352 1998 98 101
4. U Veronesi P Maisonneuve A Costa Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study Lancet 352 1998 93 97
5. JR Ross TJ Powles Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials Clin Breast Cancer 2 2001 33 36
6. AU Buzdar Tamoxifen's clinical applications: old and new Arch Fam Med 9 2000 906 912
7. KI Pritchard Is tamoxifen effective in prevention of breast cancer? Lancet 352 1998 80 81
8. RT Chlebowski DE Collyar MR Somerfield American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene J Clin Oncol 17 1999 1939 1955
9. VG Vogel Management of Patients at High Risk for Breast Cancer 2001 Blackwell Science Inc. Malden, MA
10. SM Lippman PH Brown Tamoxifen prevention of breast cancer: an instance of the fingerpost J Natl Cancer Inst 91 1999 1809 1819
11. SA Narod JS Brunet P Ghadirian Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group Lancet 356 2000 1876 1881
12. MH Gail JP Costantino J Bryant Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer J Natl Cancer Inst 91 1999 1829 1846
13. VG Vogel JC Costantino Identifying subjects for breast cancer risk reduction: an epidemiologic approach Breast Cancer Res Treat 64 2000 48 (Abstract).